NCT00924105View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

CYT013-IL1bQb

s.c. injection

DRUG

Placebo

s.c. injection

Trial Locations (3)

Unknown

Cytos Investigator sites, Hamburg

Cytos Investigator sites, Basel

Cytos Investigator sites, Zurich

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY